Psoriasis: Hope for the Future

Nursing Clinics of North America

Volumn 42, Issue 3, 2007, Pages 467-484

  Sullivan Whalen, Mary ^a   Gilleaudeau, Patricia ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; DERMATOLOGICAL AGENT; IMMUNOSUPPRESSIVE AGENT;

BIOLOGICAL THERAPY; HUMAN; METHODOLOGY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHOTOTHERAPY; PSORIASIS; PSYCHOLOGICAL ASPECT; REVIEW; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS; BIOLOGICAL THERAPY; DERMATOLOGIC AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PSORIASIS; ULTRAVIOLET THERAPY;

EID: 34548337357     PISSN: 00296465     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cnur.2007.06.003     Document Type: Review

References (21)

1. Christophers E., and Mroweitz U. Psoriasis. In: Freedberg I.M., Eisen A.Z., Wolff K., et al. (Eds). Fitzpatrick's dermatology in general medicine. 6th edition (2003), McGraw Hill, New York 407-427
2. Koo J.Y.M., and Siebenlist J. Vitamin D analogues in the treatment of psoriasis. In: Roenigk H.H., and Maibach H.I. (Eds). Psoriasis. 3rd edition (1998), Marcel Dekker, Inc., New York 497-510
3. Griffiths C.E.M., Clark C.M., Chalmers R.J.G., et al. A systematic review of treatments for severe psoriasis. Health Technol Assess 4 40 (2000) 1-125
4. Drake L.A., Ceilley R.I., Cornelison R.L., et al. Guidelines of care for psoriasis. J Am Acad Dermatol 28 4 (1993) 632-637
5. 389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1 5 (1995) 442-447
6. Wang F., Lew W., and Krueger J.G. The therapy of psoriasis based on innate and adaptive immune mechanisms of disease pathogenesis. G Ital Dermatol Venereol 139 3 (2004) 207-230
7. Grabbe S., and Schwartz T. Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity. Immunol Today 19 (1998) 37-44
8. Amin S., Cornell R.C., Stoughton R.B., et al. Topical corticosteroids. In: Roenigk H.H., and Maibach H.I. (Eds). Psoriasis. 3rd edition (1998), Marcel Dekker, Inc., New York 453-467
9. Ortel B., Liebman E.J., Honigsmann H., et al. Oral psoralen photochemotherapy. In: Roenigk H.H., and Maibach H.I. (Eds). Psoriasis. 3rd edition (1998), Marcel Dekker, Inc., New York 543-557
10. Gibson L.E., and Perry H.O. Goeckerman therapy. In: Roenigk H.H., and Maibach H.I. (Eds). Psoriasis. 3rd edition (1998), Marcel Dekker, Inc., New York 469-477
11. Roenigk H.H., and Maibach H.I. Methotrexate. In: Roenigk H.H., and Maibach H.I. (Eds). Psoriasis. 3rd edition (1998), Marcel Dekker, Inc., New York 609-629
12. Chalmers R.J.G., Kirby B., Smith A., et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol 152 (2005) 444-450
13. Koo J.Y.M., Gambla C., and Lee J. Cyclosporin for the treatment of psoriasis. In: Roenigk H.H., and Maibach H.I. (Eds). Psoriasis. 3rd edition (1998), Marcel Dekker, Inc., New York 641-658
14. Zachariae H. Long-term use of cyclosporine in dermatology. In: Roenigk H.H., and Maibach H.I. (Eds). Psoriasis. 3rd edition (1998), Marcel Dekker, Inc., New York 659-662
15. Goldfarb M.T., and Ellis C. Clinical use of etretinate and acitretin. In: Roenigk H.H., and Maibach H.I. (Eds). Psoriasis. 3rd edition (1998), Marcel Dekker, Inc., New York 663-670
16. Nussbaum R., and Krueger J.G. Treatment of inflammatory dermatoses with novel biologic agents: a primer. Adv Dermatol 18 (2002) 45-89
17. Available at: www.enbrel.com. Accessed December 1, 2006.
18. Available at: www.psoriasis.org. Accessed December 1, 2006.
19. Available at: www.raptiva.com. Accessed December 1, 2006.
20. Available at: www.remicade.com. Accessed December 1, 2006.
21. Lowes M.A., Bowcock A.M., and Krueger J.G. Pathogenesis and therapy of psoriasis. Nature 44 (2006) 866-873